Pharma-backed Mission Therapeutics stops preclinical operations, focuses on two clinical assetsnews2025-02-27T19:23:21+00:00February 27th, 2025|Endpoints News|
Kallyope quietly reports Phase 2 obesity data, begins mid-stage migraine trialnews2025-02-27T11:11:16+00:00February 27th, 2025|Endpoints News|
Eikon raises $351M Series D, pipeline advances to Phase 3news2025-02-26T12:00:08+00:00February 26th, 2025|Endpoints News|
Emalex clears Phase 3 for Tourette syndrome, will seek FDA approvalnews2025-02-25T20:18:57+00:00February 25th, 2025|Endpoints News|
Chinese ADC biotech lets Hong Kong IPO filing lapsenews2025-02-25T17:31:04+00:00February 25th, 2025|Endpoints News|
BridGene nets another Takeda deal amid plans to raise more funding and go publicnews2025-02-25T13:00:10+00:00February 25th, 2025|Endpoints News|
How Keymed steered the China-to-US NewCo model in biotechnews2025-02-20T16:20:44+00:00February 20th, 2025|Endpoints News|
EG 427 collects €27M in Series B to advance overactive bladder treatmentnews2025-02-20T11:52:50+00:00February 20th, 2025|Endpoints News|
Epitopea secures R&D deal with Merck for tumor-specific antigensnews2025-02-19T12:00:37+00:00February 19th, 2025|Endpoints News|
Exclusive: CRISPR delivery startup Spotlight Therapeutics shuts downnews2025-02-19T09:07:05+00:00February 19th, 2025|Endpoints News|
